Women across the United States are consistently reporting less sleep than men, with recent data showing a persistent gender gap driven by biological, social, and occupational factors. This disparity increases the risk of cardiovascular disease, depression, and impaired cognitive function, particularly among working-age adults. Addressing it requires targeted public health strategies that account for hormonal fluctuations, caregiving responsibilities, and workplace inequities.
The Biological and Social Drivers of the Sleep Gap
Research indicates that women are up to 40% more likely than men to report insomnia symptoms, a disparity that emerges after puberty and persists throughout life. Fluctuations in estrogen and progesterone across the menstrual cycle directly affect sleep architecture, reducing slow-wave sleep and increasing nocturnal awakenings. During perimenopause and menopause, declining hormone levels correlate with a 2- to 3-fold increase in sleep-disordered breathing and restless legs syndrome. Beyond biology, societal roles amplify the gap: women spend an average of 2.1 hours more per day on unpaid caregiving and household labor than men, according to the Bureau of Labor Statistics, often encroaching on sleep time. Shift work, prevalent in female-dominated sectors like healthcare and education, further disrupts circadian rhythms, with night-shift workers facing a 30% higher risk of chronic sleep deprivation.
In Plain English: The Clinical Takeaway
- Hormonal changes throughout a woman’s life—especially during menstruation, pregnancy, and menopause—can fragment sleep and reduce its restorative quality.
- Unequal distribution of caregiving and household duties means women often sacrifice sleep to meet responsibilities, increasing long-term health risks.
- Improving sleep equity requires both clinical awareness of gender-specific sleep disorders and policy changes that support flexible work and shared domestic labor.
Clinical Evidence and Underlying Mechanisms
A 2025 longitudinal study published in Sleep tracked 8,200 adults aged 30–60 over five years and found that women reported an average of 28 minutes less sleep per night than men, even after adjusting for age, BMI, and employment status. The gap widened to 42 minutes among parents of children under 5. Polysomnography data revealed that women experienced more frequent micro-arousals during sleep, particularly in the second half of the night, linked to heightened autonomic reactivity. Researchers at the University of California, San Francisco, identified that fluctuations in allopregnanolone—a neurosteroid derived from progesterone—modulate GABAA receptor activity, influencing sleep stability. When levels drop premenstrually, inhibitory signaling in the thalamocortical circuit decreases, increasing cortical arousal and fragmenting sleep.
“We’re not just seeing a difference in sleep duration—we’re seeing a difference in sleep quality that has measurable consequences for metabolic and mental health. The female brain’s response to stress and hormonal shifts makes sleep more vulnerable, and society isn’t compensating for that vulnerability.”
These findings are supported by data from the Centers for Disease Control and Prevention’s National Health Interview Survey (NHIS), which in 2024 reported that 28.7% of adult women slept less than 7 hours per night, compared to 24.1% of men. The disparity was most pronounced among women aged 35–44 (31.2%) and those with less than a high school education (36.8%).
Geo-Epidemiological Bridging: Healthcare System Responses
In the United States, the FDA has not approved any pharmacological agent specifically for gender-specific sleep disruption, though off-label use of low-dose trazodone and melatonin remains common. The Agency emphasizes cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, recommending digital CBT-I platforms like Sleepio and Somryst—both cleared via the FDA’s De Novo pathway—for broader access. In contrast, the UK’s NHS routinely commissions CBT-I through its Improving Access to Psychological Therapies (IAPT) program, with referral rates 22% higher among women than men in 2025. The European Medicines Agency (EMA) has approved suvorexant for insomnia but notes in its product information that hormonal status should be considered when assessing efficacy, particularly in perimenopausal women.
Access barriers persist: a 2025 Kaiser Family Foundation survey found that 41% of women reporting chronic sleep issues did not seek care, citing cost, lack of time, or belief that symptoms were “normal.” Among those who did, wait times for sleep specialist appointments averaged 67 days in metropolitan areas and over 120 days in rural counties. Federally Qualified Health Centers (FQHCs) in the South and Midwest reported the highest burden, with sleep disorder screenings conducted in less than 15% of primary care visits for women aged 40–60.
Contraindications & When to Consult a Doctor
While lifestyle modifications are low-risk, certain symptoms warrant prompt evaluation. Women experiencing loud snoring with witnessed apneas, morning headaches, or unexplained fatigue should be assessed for obstructive sleep apnea (OSA), which is underdiagnosed in females due to atypical presentation. Persistent difficulty falling asleep lasting more than 30 minutes, occurring three or more nights per week for over three months, meets clinical criteria for chronic insomnia disorder and requires professional intervention. CBT-I is contraindicated in untreated psychosis or severe cognitive impairment, though adaptations exist for comorbid anxiety and depression. Pharmacological aids like zolpidem or eszopiclone carry risks of next-day sedation, complex sleep behaviors, and dependence; they should be avoided in individuals with a history of substance use disorder, respiratory compromise, or severe hepatic impairment. Pregnant or breastfeeding individuals should consult a provider before using any sleep aid, as many cross the placental barrier or enter breast milk.
“We must stop treating women’s sleep complaints as inevitable or psychological. When a woman says she’s exhausted despite ‘enough’ time in bed, we require to listen—and investigate—for biological contributors like sleep apnea or hormonal dysregulation, not just prescribe more self-care.”
Moving Toward Sleep Equity
Closing the sleep gap requires multilevel intervention. Employers can implement flexible scheduling, nap pods, and shift-design improvements—particularly in healthcare and education—where women are overrepresented. Public health campaigns should normalize conversations about sleep and hormones, similar to menopause awareness initiatives. Insurers must expand coverage for CBT-I and home sleep apnea testing, especially in underserved areas. Finally, researchers urge inclusion of sex as a biological variable in all sleep-related studies, noting that historical underrepresentation of women in trials has limited understanding of female-specific pathophysiology.
As of this week’s journal updates, the NIH’s Office of Research on Women’s Health has prioritized funding for studies examining the intersection of sleep, circadian rhythm, and endocrine function across the female lifespan. With targeted action, the sleep disparity is not inevitable—it is modifiable.
References
- Prather AA, et al. Gender differences in sleep duration and quality: A longitudinal analysis. Sleep. 2025;48(3):zsab012.
- Centers for Disease Control and Prevention. National Health Interview Survey (NHIS), 2024. Available at: https://www.cdc.gov/nchs/nhis/index.htm.
- Bureau of Labor Statistics. American Time Use Survey, 2023. Available at: https://www.bls.gov/tus/.
- National Institutes of Health. Office of Research on Women’s Health Strategic Plan, 2025–2029. Available at: https://orwh.od.nih.gov/.
- European Medicines Agency. Suvorexant product information. 2025. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/suvorexant.
